Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Telik Inc. Stories

2011-11-10 08:00:00

PALO ALTO, Calif., Nov. 10, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today two clinical presentations at the 53rd Annual Meeting of the American Society of Hematology in San Diego, California. Details of the presentations are as follows: Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic...

2011-11-03 15:05:00

PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $2.8 million, or $0.05 per share, for the third quarter ended September 30, 2011, compared with a net loss of $4.7 million, or $0.09 per share, for the comparable period in 2010. For the quarter ended September 30, 2011, total operating costs and expenses were $2.9 million, compared with $4.7 million in the third quarter of 2010. Operating expenses in the 2011 third quarter included...

2011-11-03 08:00:00

PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication in the Journal of Hematology & Oncology of: Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): A case report of complete response of a patient with G-CSF resistant severe chronic idiopathic neutropenia following treatment with Telintra; Roger M. Lyons, MD et al. from the Cancer Care Centers of South Texas; Journal of Hematology...

2011-11-01 08:00:00

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the presentation of mechanistic studies on Telintra and related analogs at the 2011 Meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California. Details of the presentation are as follows: Novel Ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit...

2011-10-13 08:00:00

PALO ALTO, Calif., Oct. 13, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2b clinical trial to evaluate Telintra treatment of patients with Low to Intermediate-1 IPSS Risk, transfusion dependent, non-deletion (5q) myelodysplastic syndrome (MDS), who have not been treated with hypomethylating agents (HMA) such as Vidaza® or Dacogen®. This patient population represents the majority of MDS patients and a...

2011-09-29 08:00:00

PALO ALTO, Calif., Sept. 29, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication in the journal Cancer of A Phase 2 Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS), Raza, A., et al., Cancer, doi: 10.1002/cncr.26469, September 1, 2011. The publication may be found at http://onlinelibrary.wiley.com/doi/10.1002/cncr.26469/abstract. A significant finding of the study was that...

2011-08-11 15:05:00

PALO ALTO, Calif., Aug. 11, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $3.0 million, or $0.06 per share, for the second quarter ended June 30, 2011, compared with a net loss of $4.9 million, or $0.09 per share, for the comparable period in 2010. For the quarter ended June 30, 2011, total operating costs and expenses were $3.0 million, compared with $5.0 million in the 2010 second quarter. Operating expenses in the 2011 second quarter included stock-based...

2011-06-07 15:05:00

PALO ALTO, Calif., June 7, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS). This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a sequential design with two interim analyses. These patients are transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will be...

2011-05-16 15:05:00

PALO ALTO, Calif., May 16, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2011. The net loss for the quarter ended March 31, 2011 was $3.7 million, or $0.07 per share, compared with a net loss of $5.3 million, or $0.10 per share, for the same period in 2010. Total research and development expenses (R&D) in the first quarter of 2011 were $1.7 million, compared to $2.8 million for the same period in 2010. The...

2011-04-05 07:00:00

PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today presented data at the 102nd American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida on a group of second generation analogs of ezatiostat, the most clinically advanced product in development at Telik. Ezatiostat is the first inhibitor of glutathione-S-transferase P1-1 (GST P-1), a validated enzyme target in Myelodysplastic Syndrome (MDS), to successfully complete a Phase 2 clinical...